2025
1840-P: Pyruvate Kinase Bioenergetically Restricts OXPHOS in Beta Cells and Myotubules by Inducing Mitochondrial Membrane Hyperpolarization
DAVIDSON E, KIBBEY R. 1840-P: Pyruvate Kinase Bioenergetically Restricts OXPHOS in Beta Cells and Myotubules by Inducing Mitochondrial Membrane Hyperpolarization. Diabetes 2025, 74 DOI: 10.2337/db25-1840-p.Peer-Reviewed Original ResearchMitochondrial membrane potentialPyruvate kinaseHyperpolarization of mitochondrial membrane potentialRespiratory suppressionMitochondrial membrane potential differenceMitochondrial membrane hyperpolarizationCytosolic ATP/ADP ratioComplex V activityDigestive and Kidney DiseasesINS-1ATP hydrolysisATP synthesisPhosphoenolpyruvateMembrane hyperpolarizationPK substratesBlocking electron transportOXPHOSKidney diseaseATP/ADP ratioBeta cellsHyperpolarizationMembrane potentialPK activityState 3OligosPart II. Dermatologic Manifestations Associated with Treatment of Patients with Kidney Disease
Singal A, Cowper S, Ko C, Kroshinsky D, Lipner H, Robinson-Bostom L, Yosipovitch G, Lipner S. Part II. Dermatologic Manifestations Associated with Treatment of Patients with Kidney Disease. Journal Of The American Academy Of Dermatology 2025 PMID: 40543663, DOI: 10.1016/j.jaad.2025.06.034.Peer-Reviewed Original ResearchEnd stage kidney diseaseKidney diseaseMultidisciplinary team-based approachTreatment of patientsNephrogenic systemic fibrosisStage kidney diseaseClinical presentationSteal syndromeAffected patientsDermatological manifestationsSystemic fibrosisPatientsDialysis-related amyloidosisTeam-based approachUnique treatmentDiseaseCalciphylaxisFibrosisSyndromeDermatosesDermatologistsKidneyAmyloidosisPart I. Dermatologic Manifestations in Patients with Kidney Disease
Singal A, Liu J, Cowper S, Ko C, Kroshinsky D, Lipner H, Robinson-Bostom L, Yosipovitch G, Lipner S. Part I. Dermatologic Manifestations in Patients with Kidney Disease. Journal Of The American Academy Of Dermatology 2025 PMID: 40543664, DOI: 10.1016/j.jaad.2025.06.035.Peer-Reviewed Original ResearchChronic kidney diseaseChronic kidney disease patientsDermatological manifestationsKidney diseaseLack of consensus guidelinesAvoidance of complicationsCKD-associated pruritusPorphyria cutanea tardaUremic frostHistopathological presentationPrompt recognitionConsensus guidelinesPigmentary changesDifferential diagnosisPerforating disordersNail changesCutanea tardaDermatological diseasesPatientsUnique dermatosisDiseaseManifestationsComplicationsPruritusDermatosesCorrection: Prevalence of chronic kidney disease among young people living with HIV in Sub Saharan Africa: A systematic review and meta-analysis
Nasuuna E, Nanyeenya N, Kibirige D, Izudi J, Chikwari C, Kalyesubula R, Castelnuovo B, Tomlinson L, Weiss H. Correction: Prevalence of chronic kidney disease among young people living with HIV in Sub Saharan Africa: A systematic review and meta-analysis. PLOS ONE 2025, 20: e0326624. PMID: 40526591, PMCID: PMC12173373, DOI: 10.1371/journal.pone.0326624.Peer-Reviewed Original ResearchUremic toxin receptor NR1H3 contributes to hyperlipidemia- and chronic kidney disease-accelerated vascular inflammation, which is partially suppressed by novel YBX2 anti-ROS pathway
Lu Y, Sun Y, Saaoud F, Xu K, Shao Y, Han B, Jiang X, Martinez L, Vazquez-Padron R, Mohsin S, Zhao H, Wang H, Yang X. Uremic toxin receptor NR1H3 contributes to hyperlipidemia- and chronic kidney disease-accelerated vascular inflammation, which is partially suppressed by novel YBX2 anti-ROS pathway. Redox Biology 2025, 85: 103724. PMID: 40505347, PMCID: PMC12182350, DOI: 10.1016/j.redox.2025.103724.Peer-Reviewed Original ResearchChronic kidney diseaseReactive oxygen speciesROS regulationNephrectomy-induced chronic kidney diseaseVascular inflammationRNA-binding proteinsReactive oxygen species regulationPromote vascular inflammationPromotion of inflammationCellular ROS levelsTrained immunityDisease progressionKidney diseaseMouse modelCytokine genesMouse aortaProinflammatory genesTranscription factorsRisk factorsRegulating inflammationHyperlipidemiaCardiovascular diseaseInflammationNegative feedback mechanismYBX2Role of Chimeric Antigen Receptor–Expressing Cell Therapy in Immune-Mediated Kidney Diseases: A Review
Peng J, Zhang Y, Wang J, Zhang H, Schett G. Role of Chimeric Antigen Receptor–Expressing Cell Therapy in Immune-Mediated Kidney Diseases: A Review. American Journal Of Kidney Diseases 2025 PMID: 40484342, DOI: 10.1053/j.ajkd.2025.04.012.Peer-Reviewed Original ResearchImmune-mediated kidney diseasesB-cell depletionB cellsKidney diseaseCell therapyPlasma cellsTreatment of immune-mediated kidney diseasesB-cell-depleting monoclonal antibodyB-cell targeted therapiesComplete B-cell depletionAutoantibody-producing plasma cellsDeplete plasma cellsMonoclonal antibodiesAntigen-presenting cellsAdaptive immune responsesImmune-mediatedSelf-antigensT cellsImmune cellsImmune responseTherapyInfiltrated tissuesDiseaseAntibodiesCellsFertile Ground for Mathematical Modeling: Therapeutic and Diagnostic Nanoparticle Transport in the Glomerulus
Richfield O, Cortez R, Navar L, Pober J, Zheng J, Saltzman W. Fertile Ground for Mathematical Modeling: Therapeutic and Diagnostic Nanoparticle Transport in the Glomerulus. Regenerative Engineering And Translational Medicine 2025, 1-17. DOI: 10.1007/s40883-025-00424-x.Peer-Reviewed Original ResearchChronic kidney diseaseGlomerular diseaseTreat glomerular diseasesKidney diseaseMaintenance of fluid balanceGlomerular filtration barrierTherapeutic optionsGlomerular hemodynamicsGlomerular pathologyFluid balanceGlomerular cellsGlomerular dysfunctionKidney failureRenal glomeruliGlomeruliHuman kidneyGlomerular capillariesNanoparticle transportUrine formationDiseaseFiltration barrierNP transportKidneyNP interactionsPhysiological maintenanceUpdate on Acute Tubulointerstitial Nephritis: Clinical Features, Immunologic Insights, and Diagnostic and Treatment Approaches
Sahutoglu T, Perazella M. Update on Acute Tubulointerstitial Nephritis: Clinical Features, Immunologic Insights, and Diagnostic and Treatment Approaches. Kidney International Reports 2025, 10: 1643-1656. DOI: 10.1016/j.ekir.2025.03.050.Peer-Reviewed Original ResearchAcute tubulointerstitial nephritisAcute kidney injuryC-reactive proteinAcute kidney diseaseTubulointerstitial nephritisType IV hypersensitivity mechanismKidney diseaseAcute kidney injury etiologyTh2-mediated immune responsesSerum C-reactive proteinTriggered by medicationsTumor necrosis factor (TNF)-aInterleukin (IL)-9Urinary retinol-binding proteinT helper (Th)1T cell polarizationIrreversible kidney damageInflammatory endotypesImprove patient outcomesPrompt diagnosisKidney biopsyT cellsClinical featuresDiagnostic challengeImmune heterogeneityExecutive summary for the China Kidney Disease Network (CK-NET) 2017–2018 Annual Data Report
Yang C, Gao B, Wang F, Chu H, Wang J, Sun X, Zhang P, Xu H, Mao H, Xing C, Chen M, Zuo L, Wang Y, Yu F, Zhang H, Wang H, Chen J, Zhang L, Zhao M, Group C. Executive summary for the China Kidney Disease Network (CK-NET) 2017–2018 Annual Data Report. Kidney International 2025, 107: 980-984. PMID: 40404261, DOI: 10.1016/j.kint.2024.12.017.Peer-Reviewed Original ResearchThe Discrepancy Between Estimated GFR Cystatin C and Estimated GFR Creatinine at 3 Months After Hospitalization and Long-Term Adverse Outcomes
Wen Y, Srialluri N, Farrington D, Thiessen-Philbrook H, Menez S, Moledina D, Coca S, Ikizler T, Siew E, Go A, Hsu C, Himmelfarb J, Chinchilli V, Kaufman J, Kimmel P, Garg A, Grams M, Parikh C. The Discrepancy Between Estimated GFR Cystatin C and Estimated GFR Creatinine at 3 Months After Hospitalization and Long-Term Adverse Outcomes. Kidney International Reports 2025, 10: 1896-1906. DOI: 10.1016/j.ekir.2025.04.003.Peer-Reviewed Original ResearchAcute kidney injuryEnd-stage kidney diseaseHeart failure hospitalizationFailure hospitalizationCystatin CHospitalized adultsRisk of heart failure hospitalizationHigher risk of heart failure hospitalizationLong-term adverse outcomesMedian follow-upRisk of end-stage kidney diseaseAge of study participantsPrognostic valuePrognostic markerCardiac eventsKidney injuryRisk stratificationFollow-upAdverse outcomesKidney diseaseEGFRcrHospitalized patientsHigh riskSurvival analysisEGFRcysImpact of improved diagnosis and treatment on holistic chronic kidney disease burden
Tangri N, Priest S, Zara A, Long B, Chen J, Rao N, Froguel C, Robson B, Guldemond N, Eckelman M, Moura A, Audehm R, Adshead F, Zhao M, Wanner C, Chadban S. Impact of improved diagnosis and treatment on holistic chronic kidney disease burden. Kidney International Reports 2025 DOI: 10.1016/j.ekir.2025.05.039.Peer-Reviewed Original ResearchGuideline-directed medical therapyChronic kidney diseaseKidney replacement therapyGDMT adherenceImpact of chronic kidney diseaseTreatment of chronic kidney diseaseBurden of chronic kidney diseaseDelay CKD progressionChronic kidney disease burdenHealthcare systemMedical therapyReplacement therapyAdherence scenariosCKD progressionCardiovascular eventsUndertreated diseaseGuideline changesMultiple therapiesAvailability of effective interventionsLipid loweringKidney protectionKidney diseaseCKD modelGlucose loweringLifestyle interventionTrends of preemptive kidney transplantation in lupus compared to other primary diseases leading to end stage kidney disease in the United States of America
Contreras G, Pagan J, Elfassy T, Bandes M, Bustamante N, Ortigosa-Goggins M, Becerra L, Mendoza J, Drexler Y, Alonso S, Roth D. Trends of preemptive kidney transplantation in lupus compared to other primary diseases leading to end stage kidney disease in the United States of America. Lupus 2025, 34: 775-786. PMID: 40391526, DOI: 10.1177/09612033251344189.Peer-Reviewed Original ResearchConceptsKidney allograft failurePreemptive kidney transplantationEnd-stage kidney diseasePolycystic kidney diseaseRisk of kidney allograft failureAll-cause mortalityUnited States Renal Data SystemNon-lupusGlomerular diseaseKidney diseaseDM recipientsLupus patientsKidney transplantationRisk of all-cause mortalityNon-lupus patientsEnd stage kidney diseaseIncident ESKD patientsStage kidney diseaseCochran-Armitage testAllograft failurePrimary diseasePoor outcomeHypertensionLupusPatientsAutosomal Dominant Polycystic Kidney Disease
Chebib F, Hanna C, Harris P, Torres V, Dahl N. Autosomal Dominant Polycystic Kidney Disease. JAMA 2025, 333: 1708-1719. PMID: 40126492, DOI: 10.1001/jama.2025.0310.Peer-Reviewed Original ResearchMeSH KeywordsAdultAneurysm, RupturedAntidiuretic Hormone Receptor AntagonistsDisease ProgressionGlomerular Filtration RateHumansHypertensionIntracranial AneurysmKidneyPolycystic Kidney, Autosomal DominantRenal Insufficiency, ChronicRenal Replacement TherapySeverity of Illness IndexTolvaptanTreatment OutcomeTRPP Cation ChannelsConceptsAutosomal dominant polycystic kidney diseaseMayo imaging classificationRate of eGFR declineKidney replacement therapyEGFR declineDevelopment of kidney cystsKidney diseaseKidney failureReplacement therapyMm HgVasopressin type 2 receptor antagonist tolvaptanProgression to kidney replacement therapyAnnual rate of eGFR declineAdequate hydrationIntracranial aneurysmsManagement of Autosomal Dominant Polycystic Kidney DiseaseWeight managementProgression to kidney failureDietary sodium restrictionFirst-line treatmentKidney cystsSeverity of kidney diseaseTotal kidney volumeDominant polycystic kidney diseaseDe novo diseaseAutosomal dominant polycystic kidney disease without apparent family history: A single-center experience.
Samuels M, Maarouf O, Zeng W, Hamrahian M, Dahl N, Zhang J. Autosomal dominant polycystic kidney disease without apparent family history: A single-center experience. Clinical Nephrology 2025 PMID: 40329829, DOI: 10.5414/cn111677.Peer-Reviewed Original ResearchAutosomal dominant polycystic kidney diseaseDisease-causing variantsDominant polycystic kidney diseaseFamily historyPolycystic kidney diseaseAutosomal dominant polycystic kidney disease phenotypeKidney diseaseHistory of autosomal dominant polycystic kidney diseaseFamily history of autosomal dominant polycystic kidney diseaseSingle-center experienceApparent family historyThomas Jefferson University HospitalGenetic test resultsADPKD patientsPKD patientsKidney functionGenetic diagnosisGenetic testingUniversity HospitalAccurate diagnosisPatientsKidney failureClinical diagnosisDisease accountPracticing nephrologistsIntracranial Aneurysms in Autosomal Dominant Polycystic Kidney Disease: A Practical Approach to Screening and Management
Borghol A, Alkhatib B, Zayat R, Ravikumar N, Munairdjy Debeh F, Ghanem A, Mina J, Mao M, Dahl N, Hickson L, Aslam N, Torres V, Brown R, Tawk R, Chebib F. Intracranial Aneurysms in Autosomal Dominant Polycystic Kidney Disease: A Practical Approach to Screening and Management. Mayo Clinic Proceedings 2025, 100: 1030-1050. PMID: 40319406, DOI: 10.1016/j.mayocp.2025.02.003.Peer-Reviewed Original ResearchConceptsAutosomal dominant polycystic kidney diseaseDominant polycystic kidney diseasePolycystic kidney diseaseIntracranial aneurysmsSubarachnoid hemorrhageFamily history of intracranial aneurysmsProgressive kidney function declineKidney diseaseSymptoms related to mass effectRisk factorsBrain magnetic resonance angiographyHistory of intracranial aneurysmsControl of risk factorsFocal neurological deficitsFollow-up careKidney function declineGenetic kidney disordersCharacteristics of intracranial aneurysmsIndicator of subarachnoid hemorrhageMagnetic resonance angiographyNonmodifiable risk factorsPrevent adverse outcomesSaccular intracranial aneurysmsCase-fatality rateThunderclap headacheCharacterizing the ADPKD-IFT140 Phenotypic Signature with Deep Learning and Advanced Imaging Biomarkers
Ghanem A, Debeh F, Borghol A, Zagorec N, Tapia A, Smith B, Paul S, Basit A, AlKhatib B, Nader N, Antoun M, Gregory A, Yang H, Schauer R, Dahl N, Hanna C, Torres V, Kline T, Harris P, Gall E, Chebib F. Characterizing the ADPKD-IFT140 Phenotypic Signature with Deep Learning and Advanced Imaging Biomarkers. Kidney International Reports 2025 DOI: 10.1016/j.ekir.2025.04.062.Peer-Reviewed Original ResearchArea under the curveHeight-adjusted total kidney volumeAutosomal dominant polycystic kidney diseaseEstimated glomerular filtrationDisease-causing variantsDevelopment cohortAdvanced imaging biomarkersTotal kidney volumeDominant polycystic kidney diseaseRetrospective cohort studyPolycystic kidney diseaseClinical presentationCyst volumeKidney volumeCyst diameterCystic indexDiverse clinical settingsLiver cystsCohort studyExternal cohortKidney diseaseLarge cystsInternational cohortGlomerular filtrationPatientsOutcomes of chronic limb-threatening ischemia revascularization in patients with chronic kidney disease in the BEST-CLI trial Presented at the Southern Association for Vascular Surgery Forty-ninth Annual Meeting, Frenchman's Reef in St. Thomas, USVI, January 22-25, 2025.
Malas M, Hamouda M, Farber A, Menard M, Conte M, Rosenfield K, Strong M, Doros G, Powell R, Mena-Hurtado C, Gasper W, Schermerhorn M, Allievi S, Smolderen K, Dake M, Rymer J, Tuttle K. Outcomes of chronic limb-threatening ischemia revascularization in patients with chronic kidney disease in the BEST-CLI trial Presented at the Southern Association for Vascular Surgery Forty-ninth Annual Meeting, Frenchman's Reef in St. Thomas, USVI, January 22-25, 2025. European Journal Of Vascular And Endovascular Surgery 2025, 69: e262-e263. DOI: 10.1016/j.ejvs.2025.02.053.Peer-Reviewed Original ResearchPolycystic Kidney Disease in Children: The Current Status and the Next Horizon
Cadnapaphornchai M, Dell K, Gimpel C, Guay-Woodford L, Gulati A, Hartung E, Liebau M, Mallett A, Marlais M, Mekahli D, Piccirilli A, Seeman T, Tindal K, Winyard P. Polycystic Kidney Disease in Children: The Current Status and the Next Horizon. American Journal Of Kidney Diseases 2025 PMID: 40113156, DOI: 10.1053/j.ajkd.2025.01.022.Peer-Reviewed Original ResearchAutosomal recessive polycystic kidney diseaseAutosomal dominant polycystic kidney diseasePolycystic kidney diseaseKidney diseaseFetal lifePathogenic mechanismsUrinary concentrating defectProgressive chronic kidney diseaseRecessive polycystic kidney diseaseDominant polycystic kidney diseaseChronic kidney diseaseAdult-onset diseaseDiagnostic modalitiesConcentrating defectPortfolio of clinical trialsTherapeutic managementClinical trialsInherited disorderBurden of diseaseClinical assessmentKidney cystsTherapeutic targetCilia dysfunctionAge groupsDiseaseAdding insult to injury: the spectrum of tubulointerstitial responses in acute kidney injury
Baker M, Cantley L. Adding insult to injury: the spectrum of tubulointerstitial responses in acute kidney injury. Journal Of Clinical Investigation 2025, 135: e188358. PMID: 40091836, PMCID: PMC11910233, DOI: 10.1172/jci188358.Peer-Reviewed Original ResearchConceptsAcute kidney injuryTubular epithelial cellsKidney injuryTubular cellsCases of acute kidney injuryImmune-mediated processPersistence of inflammationBiphasic immune responseChronic kidney diseaseCell deathTubular cell injuryLymphocyte subsetsTubular repairCell cycle arrestOutflow obstructionTEC differentiationPreclinical findingsLymphocytic infiltrationProinflammatory macrophagesKidney diseaseModulate inflammationImmune responseActivated macrophagesMetabolic reprogrammingTubular castsBiomarkers in Autosomal Dominant Tubulointerstitial Kidney Disease
Li M, Jiang L, Liu Z, You R, Li Y, Xiang C, Yang L, Zhang H, Zhou X. Biomarkers in Autosomal Dominant Tubulointerstitial Kidney Disease. Integrative Medicine In Nephrology And Andrology 2025, 12 DOI: 10.1097/imna-d-24-00050.Peer-Reviewed Original ResearchAutosomal dominant tubulointerstitial kidney diseaseChronic kidney diseaseTubulointerstitial kidney diseaseKidney diseaseProgressive chronic kidney diseaseDelay kidney failureVariable clinical featuresUric acid levelsControl blood pressureRenal interstitial fibrosisImprove patient outcomesPotential therapeutic targetClinical featuresClinical manifestationsTreatment optionsInterstitial fibrosisInsidious onsetClinical indicationsDisease progressionTubular proteinuriaEarly diagnosisBlood pressurePathological featuresAdvanced stageKidney failure
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply